VESPA
13.2.2024 15:01:32 CET | Business Wire | Press release
Vespa, supplier of the leading platform for applications that leverage AI and data online at scale, today announced it has earned recognition as a leader and forward mover in the GigaOm Sonar for Vector Databases.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240213670564/en/
GigaOm Sonar Reports evaluate technology that is new, interesting, and attractive but poses intrinsic risk when it comes to enterprise adoption. These reports give you the right information at the right time to help plan your strategy. Vespa is positioned as a Leader and Forward Mover in GigaOm's latest report on vector databases. (Graphic: Business Wire)
The research cites Vespa as a platform leader “because of its widespread embedding flexibility, rapid time for updating, and hybrid search capabilities–with neural network rankings. These are critical to maximizing the ROI for vector similarity search engines.”
Andrew Brust, Analyst, GigaOm: “Interest in the vector database market is surging as industries seek advanced AI to manage vast unstructured data. Vespa is well placed in this market with strengths that include model versatility, search flexibility and real-time capabilities.”
Daniel Doro, Director of Engineering, Search, Spotify: “As a reliable and scalable solution, Vespa has been instrumental in enabling Search at Spotify. We look forward to continuing our work with the Vespa team and enabling innovation that will enhance the experience for Spotify listeners.”
Jungwon Byun, COO & Cofounder, Elicit: “Vespa is a battle-tested platform that allows us to integrate keyword and vector search seamlessly. It forms a key part of our AI research solution, guaranteeing precision and rapidity in streamlining research processes. We highly recommend Vespa for its reliability and efficiency.”
Jon Bratseth, CEO and Founder, Vespa: “We are pleased to be recognized as a leader in an emerging, highly relevant, and rapidly growing market. AI is getting significant attention for its role in solving today's data challenges found in eCommerce, digital media, financial services and other industries. Vespa enables organizations to realize this opportunity. GigaOm brings clarity to this crowded and hype laden market.”
In October 2023, Vespa was spun out from Yahoo as an independent company, although the technology has existed for over a decade. Yahoo remains a key investor with Vespa technology underpinning approximately 150 applications that are integral to Yahoo’s operations.
The GigaOm Sonar for Vector Databases can be downloaded here:
https://content.vespa.ai/gigaom-report-2024
About Vespa
Vespa is a platform for applications which leverage AI and data to deliver experiences to end users online in real time, such as search, recommendation, personalization, and retrieval-augmented generation (RAG). Vespa automatically organizes data, inference and logic to allow applications to work with any amount of data, queries, and is available both as a managed service and as open source.
About Elicit
Elicit is the first AI research assistant using language models to automate research workflows like literature review. Over 250,000 researchers in leading academic and industry labs around the world use Elicit every month to summarize papers and extract insights at scale.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240213670564/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Takeda Receives U.S. FDA Approval of MIMRYLO™ (rusfertide), Marking a Potential Shift in the Treatment Paradigm for Polycythemia Vera29.8.2026 00:40:00 CEST | Press release
MIMRYLO, a First-in-Class Medicine with a Unique Mechanism of Action, is Approved for the Treatment of Erythrocytosis in Adults with Polycythemia Vera (PV)MIMRYLO Has Been Shown to Maintain Hematocrit Control, the Primary Treatment Goal in PV, as Well as Reduce Phlebotomy Burden and Improve FatigueApproval Supported by Phase 3 VERIFY Results Showing 76.9% of Patients Achieved Clinical Response During Weeks 20-32 Takeda (TSE:4502/NYSE:TAK)announced U.S. Food and Drug Administration (FDA) approval of the New Drug Application (NDA)* for MIMRYLO™ (rusfertide) for the treatment of erythrocytosis in adults with polycythemia vera (PV), a blood cancer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260824773270/en/ MIMRYLO Logo MIMRYLO is a first-in-class hepcidin mimetic designed to regulate iron distribution in the body and red blood cell overproduction to control hematocrit levels, which is the ratio of red blood cells to the tot
Rigaku and Tohoku University Establish a New Research Institute for X-Ray Metrology28.8.2026 16:00:00 CEST | Press release
Rigaku Corporation, a group company of Rigaku Holdings and a global solutions partner for X-ray analytical systems (Head Office: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), and Tohoku University (Sendai, Miyagi; President: Teiji Tominaga; “Tohoku University”) have established the Rigaku-Tohoku University Co-Creation Research Institute for X-ray Metrology: Beyond The Limits (the “Institute”) at Tohoku University on August 1, 2026. The Institute will advance X-ray metrology technology, develop new metrology methods, and foster the next generation of researchers through an initial three-year collaboration, with the possibility of extension based on its achievements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828688510/en/ Inside the Institute As semiconductors become smaller, more multilayered, and incorporate a wider range of materials, manufacturing processes are becoming increasingly complex. X-ray me
BLK: Portfolio Company of Enry’s Island S.p.A., Lists on Euronext Dublin28.8.2026 15:34:00 CEST | Press release
Enry’s Island S.p.A. (WBAG:EIOS), an international venture builder with headquarters in the Tremiti Islands and the Metaverse, announces that BLK Global PLC, one of the portfolio companies within its ecosystem, has successfully completed its admission to trading on Euronext Access Dublin. Trading in the company’s shares commenced on Friday, July 31, 2026, under ticker BLKX and ISIN GB00BPSKS130. BLK was one of the thousands of applications received by Enry’s Island which, following an assessment process based on the Enry’s Model, was selected for a one-year incubation and acceleration programme. The programme supported the company through its subsequent growth stages, ultimately leading to its current stock market listing. Alessandro Pacciana, Investor Relations Manager of Enry’s Island S.p.A., said: “BLK’s listing is the second stock market listing in two years among Enry’s Island’s portfolio companies, while Enry’s Island itself is the world’s first listed venture builder. We are pro
Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 11:00:00 CEST | Press release
Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026 The approval is based on data from the Phase 3 RISE-PD trial where Hopledo® demonstrated a significant increase in Good ON time compared with immediate-release LD/CD with fewer daily doses and a comparable safety profile Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely
MTG-I2 Safely in Orbit, Unlocking Faster and Sharper Weather Monitoring Across Europe28.8.2026 10:16:00 CEST | Press release
The Meteosat Third Generation Imager 2 satellite (MTG-I2) has successfully passed its first critical post-launch milestones, completing the first full Meteosat Third Generation constellation in orbit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828243790/en/ Credit: Arianespace livestream The imager satellite MTG-I2 is safely in orbit and operating as expected following its successful launch yesterday at 22:11 CEST on board an Ariane 6 rocket from Europe’s Spaceport in French Guiana. Our teams have established communication with the spacecraft, which has also deployed its solar panels to ensure its autonomous production of energy. MTG-I2 is in perfect shape to start its Launch and Early Operations Phase that will bring it to a higher orbit, 36 000km above Earth over the following two weeks, where a longer period of calibration and validation of its instruments will begin. This summer’s extreme weather and wildfires hav
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom